$NVET Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Nexvet Biopharma plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Nexvet Biopharma plc. Get notifications about new insider transactions in Nexvet Biopharma plc for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Sell | D | 6.72 | 6,195 | 41,630 | 0 | 6.2 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Sell | D | 6.72 | 10,800 | 72,576 | 0 | 10.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Sell | D | 6.72 | 16,400 | 110,208 | 0 | 16.4 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | D | 15.00 | 100,000 | 1,500,000 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | D | 0.13 | 48,750 | 6,094 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | D | 0.13 | 27,500 | 3,438 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Sell | D | 6.72 | 18,724 | 125,825 | 0 | 18.7 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Sell | D | 6.72 | 21,239 | 142,726 | 0 | 21.2 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Sell | D | 6.72 | 67,750 | 455,280 | 0 | 67.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Sell | D | 6.72 | 144,364 | 970,126 | 0 | 144.4 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Sell | D | 6.72 | 10,800 | 72,576 | 0 | 10.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | HORN JURGEN | Chief Product Devel ... | Option Exercise | D | 0.13 | 47,250 | 5,906 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | HORN JURGEN | Chief Product Devel ... | Option Exercise | D | 5.10 | 60,000 | 306,000 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | HORN JURGEN | Chief Product Devel ... | Sell | D | 6.72 | 15,750 | 105,840 | 0 | 15.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | D | 15.00 | 100,000 | 1,500,000 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | D | 6.35 | 52,040 | 330,454 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | D | 0.13 | 9,203 | 1,150 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | D | 0.13 | 4,833 | 604 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | D | 0.13 | 106,929 | 13,366 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | D | 0.13 | 50,000 | 6,250 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Sell | D | 6.72 | 243,587 | 1,636,905 | 0 | 243.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Sell | D | 6.72 | 109,810 | 737,923 | 0 | 109.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Sell | D | 6.72 | 1,500 | 10,080 | 0 | 1.5 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Sell | D | 6.72 | 16,020 | 107,654 | 0 | 16 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | D | 0.13 | 1,500 | 188 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Sell | D | 6.72 | 42,600 | 286,272 | 0 | 42.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | D | 15.00 | 20,000 | 300,000 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | D | 0.13 | 4,678 | 585 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | D | 0.13 | 30,000 | 3,750 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Sell | D | 6.72 | 33,180 | 222,970 | 0 | 33.2 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Sell | D | 6.72 | 18,980 | 127,546 | 0 | 19 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Option Exercise | D | 0.13 | 7,080 | 885 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Option Exercise | D | 0.13 | 3,600 | 450 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Sell | D | 6.72 | 8,800 | 59,136 | 0 | 8.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Sell | D | 6.72 | 7,200 | 48,384 | 0 | 7.2 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Option Exercise | D | 0.00 | 1,000 | 0 | 0 | |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Sell | D | 6.72 | 13,580 | 91,258 | 0 | 13.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 2,648,696 | 17,799,237 | 0 | 2.6 M to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 2,067,651 | 13,894,615 | 0 | 2.1 M to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 209,577 | 1,408,357 | 0 | 209.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 249,462 | 1,676,385 | 0 | 249.5 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 122,006 | 819,880 | 0 | 122 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 915,583 | 6,152,718 | 0 | 915.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 899,268 | 6,043,081 | 0 | 899.3 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FRIED RICHARD B | 10% Owner | Sell | U | 6.72 | 833,845 | 5,603,438 | 0 | 833.8 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 2,648,696 | 17,799,237 | 0 | 2.6 M to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 2,067,651 | 13,894,615 | 0 | 2.1 M to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 209,577 | 1,408,357 | 0 | 209.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 249,462 | 1,676,385 | 0 | 249.5 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 122,006 | 819,880 | 0 | 122 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 915,583 | 6,152,718 | 0 | 915.6 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 899,268 | 6,043,081 | 0 | 899.3 K to 0 (-100.00 %) |
| Aug 02 2017 | NVET | Nexvet Biopharma p ... | FARALLON CAPITAL MANAGEMENT LL ... | 10% Owner | Sell | U | 6.72 | 833,845 | 5,603,438 | 0 | 833.8 K to 0 (-100.00 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Buy | M | 0.13 | 3,600 | 450 | 10,800 | 7.2 K to 10.8 K (+50.00 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Buy | M | 0.13 | 3,600 | 450 | 10,800 | 7.2 K to 10.8 K (+50.00 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | HORN JURGEN | Chief Product Devel ... | Option Exercise | M | 0.13 | 15,750 | 1,969 | 47,250 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | HORN JURGEN | Chief Product Devel ... | Buy | M | 0.13 | 15,750 | 1,969 | 15,750 | 0 to 15.8 K |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | M | 0.13 | 6,194 | 774 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | M | 0.13 | 2,866 | 358 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | M | 0.13 | 2,340 | 293 | 4,678 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | M | 0.13 | 10,000 | 1,250 | 30,000 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Buy | M | 0.13 | 6,194 | 774 | 33,180 | 27 K to 33.2 K (+22.95 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Buy | M | 0.13 | 2,866 | 358 | 26,986 | 24.1 K to 27 K (+11.88 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Buy | M | 0.13 | 2,340 | 293 | 18,980 | 16.6 K to 19 K (+14.06 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Buy | M | 0.13 | 10,000 | 1,250 | 16,640 | 6.6 K to 16.6 K (+150.60 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Buy | M | 0.13 | 3,600 | 450 | 7,200 | 3.6 K to 7.2 K (+100.00 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 500 | 63 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 3,600 | 450 | 16,400 | 12.8 K to 16.4 K (+28.13 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 500 | 63 | 12,800 | 12.3 K to 12.8 K (+4.07 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 500 | 63 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Buy | M | 0.13 | 3,600 | 450 | 16,020 | 12.4 K to 16 K (+28.99 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Buy | M | 0.13 | 500 | 63 | 12,420 | 11.9 K to 12.4 K (+4.19 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | M | 0.13 | 500 | 63 | 1,500 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Buy | M | 0.13 | 3,600 | 450 | 42,600 | 39 K to 42.6 K (+9.23 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Buy | M | 0.13 | 500 | 63 | 39,000 | 38.5 K to 39 K (+1.30 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 7,079 | 885 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 4,000 | 500 | 0 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 16,250 | 2,031 | 48,750 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 65,000 | 8,125 | 27,500 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Buy | M | 0.13 | 7,079 | 885 | 21,239 | 14.2 K to 21.2 K (+49.99 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Buy | M | 0.13 | 4,000 | 500 | 67,750 | 63.8 K to 67.8 K (+6.27 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Buy | M | 0.13 | 16,250 | 2,031 | 63,750 | 47.5 K to 63.8 K (+34.21 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Buy | M | 0.13 | 13,750 | 1,719 | 47,500 | 33.8 K to 47.5 K (+40.74 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | M | 0.13 | 35,643 | 4,455 | 106,929 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | M | 0.13 | 25,000 | 3,125 | 50,000 | |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Buy | M | 0.13 | 35,643 | 4,455 | 109,810 | 74.2 K to 109.8 K (+48.06 %) |
| Jul 05 2017 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Buy | M | 0.13 | 25,000 | 3,125 | 74,167 | 49.2 K to 74.2 K (+50.85 %) |
| Apr 04 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 500 | 63 | 500 | |
| Apr 04 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 500 | 63 | 12,300 | 11.8 K to 12.3 K (+4.24 %) |
| Apr 04 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 500 | 63 | 500 | |
| Apr 04 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Buy | M | 0.13 | 500 | 63 | 11,920 | 11.4 K to 11.9 K (+4.38 %) |
| Apr 04 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | M | 0.13 | 500 | 63 | 2,000 | |
| Apr 04 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Buy | M | 0.13 | 500 | 63 | 38,500 | 38 K to 38.5 K (+1.32 %) |
| Apr 03 2017 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Option Exercise | M | 0.00 | 500 | 0 | 5,100 | |
| Apr 03 2017 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Buy | M | 0.13 | 500 | 63 | 9,480 | 9 K to 9.5 K (+5.57 %) |
| Jan 04 2017 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Option Exercise | M | 0.00 | 500 | 0 | 5,600 | |
| Jan 04 2017 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Buy | M | 0.13 | 500 | 63 | 8,980 | 8.5 K to 9 K (+5.90 %) |
| Jan 03 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 500 | 63 | 1,000 | |
| Jan 03 2017 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 500 | 63 | 11,800 | 11.3 K to 11.8 K (+4.42 %) |
| Jan 03 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 500 | 63 | 1,000 | |
| Jan 03 2017 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Buy | M | 0.13 | 500 | 63 | 11,420 | 10.9 K to 11.4 K (+4.58 %) |
| Jan 03 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | M | 0.13 | 500 | 63 | 2,500 | |
| Jan 03 2017 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Buy | M | 0.13 | 500 | 63 | 38,000 | 37.5 K to 38 K (+1.33 %) |
| Nov 09 2016 | NVET | Nexvet Biopharma p ... | GEARING DAVID | Chief Scientific Of ... | Option Exercise | M | 0.13 | 9,203 | 1,150 | 0 | |
| Nov 09 2016 | NVET | Nexvet Biopharma p ... | GEARING DAVID | Chief Scientific Of ... | Buy | M | 0.13 | 9,203 | 1,150 | 292,266 | 283.1 K to 292.3 K (+3.25 %) |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 500 | 63 | 1,500 | |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 500 | 63 | 11,300 | 10.8 K to 11.3 K (+4.63 %) |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 500 | 63 | 1,500 | |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Buy | M | 0.13 | 500 | 63 | 10,920 | 10.4 K to 10.9 K (+4.80 %) |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | M | 0.13 | 500 | 63 | 3,000 | |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Buy | M | 0.13 | 500 | 63 | 37,500 | 37 K to 37.5 K (+1.35 %) |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Option Exercise | M | 0.00 | 500 | 0 | 6,100 | |
| Oct 04 2016 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Buy | M | 0.13 | 500 | 63 | 8,480 | 8 K to 8.5 K (+6.27 %) |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 3,600 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 3,600 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 65,000 | 8,125 | 65,000 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 3,600 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | HORN JURGEN | Chief Product Devel ... | Option Exercise | M | 0.13 | 63,000 | 7,875 | 63,000 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | M | 0.13 | 142,572 | 17,822 | 142,572 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 3,600 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 3,600 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Gunn George W | Director | Grant | A | 0.00 | 20,000 | 0 | 37,000 | 17 K to 37 K (+117.65 %) |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | GEARING DAVID | Chief Scientific Of ... | Option Exercise | M | 0.13 | 47,000 | 5,875 | 47,000 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Farrell Geraldine T | VP Operations, Gene ... | Option Exercise | M | 0.13 | 40,000 | 5,000 | 40,000 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | Brown Christopher Nigel | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 3,600 | |
| Sep 07 2016 | NVET | Nexvet Biopharma p ... | PATEL RAJIV A | Director | Option Exercise | A | 0.13 | 3,600 | 450 | 6,600 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | PAYNE JOHN BERNARD | Director | Buy | M | 0.13 | 3,600 | 450 | 3,600 | 0 to 3.6 K |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Option Exercise | M | 0.13 | 500 | 63 | 2,000 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 3,600 | 450 | 10,800 | 7.2 K to 10.8 K (+50.00 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | McCracken Joseph S | Director | Buy | M | 0.13 | 500 | 63 | 7,200 | 6.7 K to 7.2 K (+7.46 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 13,750 | 1,719 | 41,250 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Option Exercise | M | 0.13 | 4,000 | 500 | 4,000 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Buy | M | 0.13 | 13,750 | 1,719 | 33,750 | 20 K to 33.8 K (+68.75 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Lismore Damian T. | Chief Financial Off ... | Buy | M | 0.13 | 4,000 | 500 | 20,000 | 16 K to 20 K (+25.00 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Kilty Cormac G | Director | Buy | M | 0.13 | 3,600 | 450 | 7,200 | 3.6 K to 7.2 K (+100.00 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | M | 0.13 | 25,000 | 3,125 | 75,000 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Option Exercise | M | 0.13 | 4,833 | 604 | 4,833 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Buy | M | 0.13 | 25,000 | 3,125 | 49,167 | 24.2 K to 49.2 K (+103.45 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Heffernan Mark | Chief Executive Off ... | Buy | M | 0.13 | 4,833 | 604 | 24,167 | 19.3 K to 24.2 K (+25.00 %) |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 3,600 | 450 | 0 | |
| Jul 01 2016 | NVET | Nexvet Biopharma p ... | Hanna Ashraf | Director | Option Exercise | M | 0.13 | 500 | 63 | 2,000 |